Soligenix receives us patent allowance for its thermostabilized vaccine platform

Includes thermostabilized ebola vaccines includes nanoemulsion adjuvant compatible with lyophilization princeton, n.j. , may 23, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the united states patent and trademark office (uspto) has issued a notice of allowance for the patent application titled "compositions and methods of manufacturing trivalent filovirus vaccines.
SNGX Ratings Summary
SNGX Quant Ranking